Bijal Shah MD Of Moffitt Cancer Center Discusses KTE-X19 Phase 1 Data: Arrived At a Cell Dose, Improved Safety Profile, Achieved Overall CRI Rate Of 84.
KTE-X19 Phase 1 Data: Arrived At a Cell Dose, Improved Safety Profile, Achieved Overall CRI Rate Of 84
